Cargando…

COVID-19 and MS disease-modifying therapies

OBJECTIVE: To address concerns regarding the effect of MS disease-modifying therapies (DMTs) on the expression of coronavirus 2019 (COVID-19). METHODS: Review of the current state of knowledge regarding the viral etiology of COVID-19, mechanisms of injury by SARS-CoV-2 infection, and the effect of i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berger, Joseph R., Brandstadter, Rachel, Bar-Or, Amit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238896/ https://www.ncbi.nlm.nih.gov/pubmed/32414755 http://dx.doi.org/10.1212/NXI.0000000000000761

Ejemplares similares

Disease-modifying therapies alter gut microbial composition in MS
por: Katz Sand, Ilana, et al.
Publicado: (2018)

The COVID-19 pandemic and the use of MS disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2020)

Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
por: Smith, Tyler E, et al.
Publicado: (2022)

How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?
por: Giovannoni, Gavin
Publicado: (2022)

Outcome of MS relapses in the era of disease-modifying therapy
por: Stoppe, Muriel, et al.
Publicado: (2017)

Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
por: Holroyd, Kathryn B., et al.
Publicado: (2022)

Immunology of COVID‐19 and disease‐modifying therapies: The good, the bad and the unknown
por: Zrzavy, Tobias, et al.
Publicado: (2020)

Effect of vitamin D on MS activity by disease-modifying therapy class
por: Rotstein, Dalia L., et al.
Publicado: (2015)

Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies
por: McFaul, Derek, et al.
Publicado: (2021)

Effects of MS disease-modifying therapies on responses to vaccinations: A review.
por: Ciotti, John Robert, et al.
Publicado: (2020)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Drugs, bugs, and MS: The interplay between disease-modifying therapy and gut microbiota
por: Mangalam, Ashutosh K.
Publicado: (2018)

Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
por: Strijbis, EMM, et al.
Publicado: (2023)

Switching to second line MS disease-modifying therapies is associated with decreased relapse rate
por: Marriott, James John, et al.
Publicado: (2023)

Targeting foam cell formation in inflammatory brain diseases by the histone modifier MS‐275
por: Zierfuss, Bettina, et al.
Publicado: (2020)

LC-MS/MS Determination of Modified Nucleosides in The Urine of Parkinson’s Disease and Parkinsonian Syndromes Patients
por: Gątarek, Paulina, et al.
Publicado: (2020)

Severe Neuroinvasive West Nile Virus in Association With Anti-CD20 Monotherapy for Multiple Sclerosis
por: Thebault, Simon, et al.
Publicado: (2023)

Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS
por: Zastepa, Evelyn, et al.
Publicado: (2014)

Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
por: Manouchehri, Navid, et al.
Publicado: (2022)

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
por: D’Amico, Emanuele, et al.
Publicado: (2021)

Having it both ways: how STAT3 deficiency blocks graft-versus-host disease while preserving graft-versus-leukemia activity
por: Brandstadter, Joshua D., et al.
Publicado: (2023)

COVID-19 vaccines and multiple sclerosis disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies
por: Kister, Ilya, et al.
Publicado: (2022)

Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?
por: Maguire, Cole, et al.
Publicado: (2020)

A Modified Acyl-RAC Method of Isolating Retinal Palmitoyl Proteome for Subsequent Detection through LC-MS/MS
por: Motipally, Sree I., et al.
Publicado: (2023)

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
por: Giovannoni, Gavin
Publicado: (2020)

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
por: Simpson-Yap, Steve, et al.
Publicado: (2021)

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
por: Reder, Anthony T., et al.
Publicado: (2021)

Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy
por: Sormani, Maria Pia, et al.
Publicado: (2022)

Detecting diagnostic features in MS/MS spectra of post-translationally modified peptides
por: Geiszler, Daniel J., et al.
Publicado: (2023)

Gene variants of adhesion molecules act as modifiers of disease severity in MS
por: Dardiotis, Efthimios, et al.
Publicado: (2017)

Notch signalling in T cell homeostasis and differentiation
por: Brandstadter, Joshua D., et al.
Publicado: (2019)

MS, pregnancy and COVID-19
por: Yam, Charmaine, et al.
Publicado: (2020)

Eco-friendly UPLC-MS/MS analysis of possible add-on therapy for COVID-19 in human plasma: Insights of greenness assessment
por: El-Naem, Omnia A., et al.
Publicado: (2021)

Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19
por: Martens-Lobenhoffer, Jens, et al.
Publicado: (2022)

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
por: Sormani, Maria Pia, et al.
Publicado: (2021)

Insight in booster COVID-19 vaccine and disease modifying therapy in multiple sclerosis
por: Beard, Katherine, et al.
Publicado: (2021)

COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies
por: Garjani, Afagh, et al.
Publicado: (2021)

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment
por: Diebold, Martin, et al.
Publicado: (2019)

Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study
por: Williams, Thomas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i0opiv2ipu4uj1eub7g0g11rve